Avoid common mistakes on your manuscript.
Correction to: Adv Ther (2022) 39:3979–4002 https://doi.org/10.1007/s12325-022-02219-w
A plain language summary was retrospectively added to this publication.
Plain Language Summary
Mycosis fungoides (MF) is a rare type of cancer that develops from blood cells and mostly affects the skin. Typical symptoms in early-stage disease are red patches and/or plaques (lesions) on the skin, which are treated with therapies that are applied directly to the skin (skin-directed therapies). In later disease stages, treatments that target the entire body (systemic therapies) are used as well. Chlormethine (CL) gel is a skin-directed chemotherapy used to treat MF skin lesions. We review evidence from clinical trials and everyday clinical practice about how safe and effective CL gel is. The results show that CL gel is a well-tolerated treatment for MF. In many patients, CL gel treatment can reduce or resolve skin lesions. CL gel can be used together with other skin-directed or systemic treatments to achieve the best possible result. In some patients, positive results are seen soon after starting treatment with CL gel, while others need to be treated for several months. This is important because it means that some patients might need to continue using the gel over a longer time. It is advised to apply CL gel once daily. Some patients may have skin irritation after using CL gel, and this can be controlled by using the gel less often or by applying corticosteroids to the skin. If the skin reactions are severe, treatment may need to be stopped. Overall, the experiences collected here suggest that CL gel is an effective and safe treatment for all patients with MF.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Wehkamp, U., Ardigò, M., Papadavid, E. et al. Publisher Correction to: Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings. Adv Ther 40, 1299–1300 (2023). https://doi.org/10.1007/s12325-022-02403-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-022-02403-y